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Introduction
Theranostics refers to the use of a diagnostic agent (Dx) in tandem with a therapeutic
agent (Rx) for the personalized treatment of diseases.1 A well-known example of a
commercialized theranostic is the use of HercepTest® (Agilent, Santa Clara, CA, USA)
in combination with Herceptin® (Genentech, South San Francisco, CA, USA) for treating breast cancer.2 However, this approach requires the sequential administration of the
paired Dx/Rx agents. A more desirable and potentially straightforward approach would
be the simultaneous administration of the Dx/Rx agents to shorten procedure times
while potentially improving patient comfort. Within this context, advances in the field
of nanotechnology over the past few decades have facilitated the synthesis of nanoparticles with diverse and complementary diagnostic and therapeutic properties that can
be incorporated within a single theranostic nanoparticle.3,4 These include iron oxide
nanoparticles,5,6 carbon nanotubes,7,8 gold nanorods,9,10 dendrimers,11,12 and vesicles,13,14
of which multiple nanoparticles are already in the clinic.15,16 A key design criterion
in the synthesis of theranostic nanoparticles, in addition to their complementary Dx/
Rx properties, is that the component materials of the nanoparticles are biocompatible
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Abstract: Theranostic nanoparticles offer the potential for mixing and matching disparate
diagnostic and therapeutic functionalities within a single nanoparticle for the personalized
treatment of diseases. In this article, we present composite iron oxide-gadolinium-containing
Prussian blue nanoparticles (Fe3O4@GdPB) as a novel theranostic agent for T1-weighted
magnetic resonance imaging (MRI) and photothermal therapy (PTT) of tumors. These
particles combine the well-described properties and safety profiles of the constituent Fe3O4
nanoparticles and gadolinium-containing Prussian blue nanoparticles. The Fe 3O4@GdPB
nanoparticles function both as effective MRI contrast agents and PTT agents as determined
by characterizing studies performed in vitro and retain their properties in the presence of cells.
Importantly, the Fe3O4@GdPB nanoparticles function as effective MRI contrast agents in vivo
by increasing signal:noise ratios in T1-weighted scans of tumors and as effective PTT agents in
vivo by decreasing tumor growth rates and increasing survival in an animal model of neuroblastoma. These findings demonstrate the potential of the Fe3O4@GdPB nanoparticles to function
as effective theranostic agents.
Keywords: theranostics, Prussian blue, iron oxide, MRI, photothermal therapy, cancer
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and/or safe for human use. Therefore, a compelling starting
point would be to synthesize theranostic nanoparticles composed of materials with a known safety profile.
To this end, in this study, we describe the design, synthesis, and utilization of composite iron oxide-gadoliniumcontaining Prussian blue nanoparticles (Fe3O4@GdPB) as
theranostic agents. Our Fe3O4@GdPB contain the following:
Fe3O4, a US Food and Drug Administration (FDA)-approved
material that has been used for T2-weighted (T2W) magnetic
resonance imaging (MRI, in Combidex);16,17 Prussian blue, an
FDA-approved material used in radiation poisoning treatment
(as Radiogardase);18–20 and gadolinium, a key component
of clinical MRI contrast agents including Magnevist and
Gadovist.21,22 Earlier reports have described the synthesis of
magnetic Prussian blue nanoparticles (without gadolinium)
for T2W imaging combined with photothermal therapy (PTT)
of tumors and gene transfection or chemotherapy combined
with PTT of tumors.23–25
Building on these earlier findings, we utilize our Fe3O4@
GdPB nanoparticles for magnetically guided, T1-weighted
(T1W) imaging and PTT of tumors. Compared with T2W
images, T1W images offer several advantages including
enhanced visualization of vascular structures, key for the
entry of Dx and Rx agents into tumors, and are less prone
to artifacts such as those present in fluid-filled structures in
particular.26 Under external magnetic guidance, T1W images
offer the potential to visualize the entry of the composite
Dx/Rx agents into a tumor through its vasculature in realtime, allowing for a more precise administration of PTT
to targeted tumors. This approach can facilitate improved
tumor treatment margins, which has implications not only for
local tumor control but also in prevention of its recurrence.
In seeking to leverage these aforementioned advantages,
we describe the synthesis and characterization of composite
Fe3O4@GdPB nanoparticles. We determine the MRI and photothermal properties of the nanoparticles. Finally, as a proofof-principle, we utilize the Fe3O4@GdPB nanoparticles for
T1W MRI and PTT in an animal model of neuroblastoma,27,28
a prevalent solid tumor of childhood and a leading cause of
cancer-related death in children.29,30 The findings of our study
are crucial for further developing our composite theranostic
nanoparticles for magnetically targeted, image-guided photothermal destruction of tumors.

Materials and methods
Materials
Ultrapure water used in this study was obtained from a
Milli-Q® system (MilliporeSigma; resistivity $17.8 MΩ cm).
All chemicals were purchased from Sigma-Aldrich, and
6414
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biological reagents were purchased from Thermo Fisher
Scientific and used as supplied without further purification
unless noted otherwise.

Synthesis of Fe3O4@GdPB nanoparticles

Fe3O4@GdPB nanoparticles were synthesized using a scheme
modified from previously described studies.23–25 Briefly,
coprecipitation was used to synthesize Fe3O4 nanoparticles
where a 1:2 molar ratio of Fe2+:Fe3+ was added dropwise
into a stirred solution of 1 M NaOH.31 The resultant black
precipitate containing Fe3O4 nanoparticles was thoroughly
rinsed and dispersed in ultrapure water by centrifugation (at
least three times at 22,000× g for 10 minutes) and resuspension (using sonication to disperse the pellet, as needed). Next,
Fe3O4 nanoparticles (diluted to 1 mg/mL) were added dropwise
into a solution of K4[Fe(CN)6] (2 mM; pH =3) in a sonicator
bath with continuous stirring maintained at 50°C. The abovementioned solution was then added to a solution containing
Gd(NO3)3 and FeCl3 (2 mM; pH =3) under the sonication,
stirring, and heating conditions described earlier. Finally, the
resultant solution containing Fe3O4@GdPb nanoparticles was
rinsed and dispersed in ultrapure water as described earlier.

Characterization of the Fe3O4@GdPB
nanoparticles
The size (hydrodynamic diameter) and charge (zeta potential) distributions of the Fe3O4@GdPB nanoparticles were
compared with both Fe3O4 and GdPB nanoparticles (previously synthesized by us)32,33 using dynamic light scattering
on a Zetasizer Nano ZS (Malvern Instruments, Malvern,
UK). Multiday stability of the Fe3O4@GdPB nanoparticles in
ultrapure water was assessed by measuring their hydrodynamic
size distributions every 24 hours over 5 days using dynamic
light scattering. The visible-near infrared (NIR) spectra of
1 mg/mL suspensions of the three different types of nanoparticles in ultrapure water were measured using a Genesys
10S Ultraviolet-Visible (UV-Vis) spectrophotometer (Thermo
Fisher Scientific, Waltham, MA, USA). Transmission electron
microscopy (TEM) images of the Fe3O4 and Fe3O4@GdPB
nanoparticles were obtained by loading 5 µL of the nanoparticle suspensions separately onto copper grids (Electron
Microscopy Sciences, Hatfield, PA, USA) using a JEOL
JEM 2100 field-emission gun scanning transmission electron
microscope (TEM; JEOL, Peabody, MA, USA). Analysis of
the size distributions of the nanoparticles was performed using
ImageJ (National Institutes of Health). Energy-dispersive
X-ray spectroscopy (EDS) was performed using an INCA
250 analysis system (Oxford Instruments, Abingdon, UK)
coupled to the TEM. A total of seven scans were performed
International Journal of Nanomedicine 2017:12
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on different parts of the grid and then averaged to obtain the
relative percentages of Gd, Fe, and K.
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MRI properties of the Fe3O4@GdPB
nanoparticles
The MR relaxivities of the Fe3O4@GdPB nanoparticles were
measured using a clinical horizontal 3 T magnet (GE Healthcare, Chicago, IL, USA). Phantoms containing varying concentrations of the nanoparticles (Fe3O4, GdPB, and Fe3O4@GdPB)
were prepared in 96-well plates in 0.5% agarose solutions. A
constant temperature of 23°C was maintained for all the measurements. The phantoms were placed on a 2% solid block of
agar and secured by tape at the center of an 8-channel high definition brain coil.32,34 T1 and T2 relaxation times were measured in
the same coronal 0.5 mm thick slice. Inversion times (TI) were
varied (from 50 to 4,000 ms) to obtain T1 measurements, while
echo times (TE) were varied (from 12 to 245 ms) to obtain T2
measurements. Image processing software, OsiriX, was used
to analyze the signal intensity within a region of interest (ROI)
of the acquired images. To measure the T1 inversion, the signal
intensity was plotted against the TI values, while signal intensity
was plotted against TE values for the T2 decay curves. The data
were then fitted using the following equations:
T1 : SI = A − Be
T2 : SI = Ce

 − TI 


 T1 



 − TE 


 T2 



where SI is the signal intensity within the ROI, and A, B, and
C are positive constants. The R1 and R2 relaxation rates were
then obtained by calculating 1/T1 and 1/T2, respectively. The
relaxation rates obtained were plotted against the concentrations of the corresponding contrast agent (Gd for T1W images
and Fe for T2W images) and slopes of these plots yielded
the relaxivities of the nanoparticles.

Photothermal properties of the Fe3O4@
GdPB nanoparticles
The photothermal properties of the Fe3O4@GdPB nanoparticles were measured using aqueous dispersions of the nanoparticles irradiated using an 808 nm NIR laser (Laserglow
Technologies, Toronto, Canada), as previously described.35
The PTT capabilities of the Fe3O4@GdPB nanoparticles
were measured as a function of concentration by varying the
concentration of the nanoparticles from 0.01 to 0.2 mg/mL
at a fixed laser fluence (power density) of 1.875 W/cm2 for
10 minutes. The PTT capabilities were measured as a function
of varying laser fluence (0.625–3.125 W/cm2) by irradiating
0.1 mg/mL Fe3O4@GdPB for 10 minutes. The stability of the
International Journal of Nanomedicine 2017:12

nanoparticles as a photothermal agent was assessed by a cyclic
heating/cooling study where 1 mg/mL Fe3O4@GdPB was irradiated by the NIR laser (laser on/off times =10 minutes each).
The photothermal conversion efficiency of the Fe3O4@GdPB
nanoparticles was measured by first heating 0.1 mg/mL of the
nanoparticles with the NIR laser at a fluence of 1.875 W/cm2
for 10 minutes. The laser was then turned off, and the cooling
kinetics of the nanoparticles was measured as a function of
time. The photothermal conversion efficiency was calculated
using the following equation described by Roper et al.36
ηT =

hA (Tmax − Tamb ) − Q0
I (1 − 10 − Aλ )



Where h is the heat transfer coefficient, A is the surface area
of heat transfer of the system, Tmax is the maximum system
temperature, Tamb is the ambient temperature, Q0 is the rate
of heat input due to absorption of light energy by water, I is
the incident laser power, and Aλ is the absorbance of the
Fe3O4@GdPB at 808 nm.

Intrinsic and PTT-induced cytotoxicity
of the Fe3O4@GdPB nanoparticles

The intrinsic and PTT-induced cytotoxicity of the Fe3O4@
GdPB nanoparticles in vitro was measured using the murine
neuroblastoma cell line Neuro2a (ATCC). Briefly, Neuro2a
was seeded in 96-well plates and incubated with either
vehicle or varying concentrations of the Fe3O4@GdPB nanoparticles (0.01–0.5 mg/mL) with or without laser irradiation
using the NIR laser (1.5 W/cm2; 10 minutes). Twenty-four
hours after the treatment, cell viability was assessed using
the CellTiter-Glo luminescent cell viability assay (Promega
Corporation, Madison, WI, USA). Each treatment was conducted with at least three replicates.

Animals
All animal studies were conducted in accordance with protocols approved by the Institutional Animal Care and Use
Committee (IACUC) at Children’s National Health System
and were conducted to ensure humane care of the animals
as per the IACUC’s guidelines. For the animal studies,
4–6-week old female A/J mice were purchased from Jackson
Laboratory, and the animals were acclimated for 3–4 days
prior to commencing the studies.

Animal studies
To establish the murine neuroblastoma model, one million
Neuro2a cells suspended in phosphate-buffered saline were
submit your manuscript | www.dovepress.com
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injected subcutaneously into the shaved backs of 4–6-week
old female A/J mice. Tumor growth was monitored by routine
caliper measurements, as previously described.35,37 All treatments commenced only after the Neuro2a tumors reached
a diameter of at least 5 mm (~60 mm3). Tumor-bearing
mice were divided into three groups (n$9 mice/group):
1) untreated group: receiving no further treatment, 2) Fe3O4@
GdPB group: receiving 100 µL of 1 mg/mL Fe3O4@GdPB
by tail vein injection, and 3) Fe3O4@GdPB + magnet group:
receiving 100 µL of 1 mg/mL Fe3O4@GdPB by tail vein
injection followed by application of an external magnetic
field for 10 minutes; by externally affixing a 3,000 Gauss
magnet (0.25″×0.25″×0.25″ Nickel-plated neodymium;
K&J Magnetics Inc, Pipersville, PA, USA) to the surface of
the tumors for mice in this group. After this step, the mice
in each group were divided into two cohorts (n$4 mice/
cohort). Mice in cohort 1 were used for MRI. These mice
were immediately euthanized after the aforementioned procedures and their tumors extracted. Tumor phantoms were
prepared using 5% agarose solutions and T1W images of
these tumors were acquired and analyzed as described earlier.
Mice in cohort 2 were used for PTT. These mice were irradiated after completing application of the external magnet with
the NIR laser (1.5 W/cm2; 15 minutes). The tumor surface
temperature achieved during the laser treatment step was
measured using an i7 thermal camera (FLIR, Wilsonville,
OR, USA). Post-PTT, tumor growth, and animal survival
were monitored.

Statistical analysis
Statistically significant differences between groups were
determined by using a Student’s t-test. The log-rank test
was used to determine statistically significant differences
in survival, analyzed by generating Kaplan–Meier plots.
A P-value of ,0.05 was considered statistically significant
in all studies (denoted by *).

Results and discussion
Synthesis scheme yields Fe3O4@GdPB
nanoparticles with stable, monodisperse
size distributions, and composite
properties
The Fe 3O 4@GdPB nanoparticles were synthesized by
growing a “shell” of gadolinium-containing Prussian blue on
an iron oxide nanoparticle “core” by modifying previously
published schemes for synthesizing magnetic Prussian blue
nanoparticles (without gadolinium).23–25 This synthesis relies
on the attachment of Fe(CN6)4- onto the surface of iron oxide

6416
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nanoparticles at an acidic pH (refer “Materials and methods”
section for details), and the subsequent growth of a GdPB
shell by the reaction of Fe(CN6)4-, Fe3+, and Gd3+ on the
surface of the iron oxide nanoparticles. To determine the
properties of the Fe3O4@GdPB nanoparticles synthesized
using the presented two-step scheme (Figure 1A), we first
measured the size distributions and charges of the nanoparticles using dynamic light scattering. The synthesis yielded
monodisperse Fe3O4@GdPB nanoparticles (polydispersity index ~0.2) with a mean hydrodynamic diameter of
164.2 nm, which was higher than the mean hydrodynamic
diameters of the constituent Fe3O4 (68 nm) and GdPB (91 nm)
nanoparticles (Figure 1B). Zeta potential measurements
revealed that the Fe3O4@GdPB nanoparticles exhibited
charges (-16.5 mV) intermediate to those of the constituent Fe3O4 (-13.3 mV) and GdPB (-24.8 mV) nanoparticles
(Figure 1C). Multiday stability studies using dynamic light
scattering demonstrated that aqueous suspensions of the
Fe3O4@GdPB nanoparticles retained nearly constant size distributions over 5 days (Figure 1D). Visible-NIR spectroscopy
of equal concentrations (1 mg/mL each) of Fe3O4, GdPB,
and Fe3O4@GdPB nanoparticles demonstrated that Fe3O4@
GdPB retained the characteristic absorption band of Prussian
blue-based nanoparticles (GdPB) in the 600–900 nm range
and, as expected, demonstrated an attenuated absorption band
relative to GdPB (Figure 1E). TEM images illustrated individual Fe3O4@GdPB nanoparticles (Figure 2A) with a size
range of 28.2±8.3 nm, representing an increase in size from
the Fe3O4 core nanoparticles (without GdPB) that had a size
range of 8.0±2.2 nm (Figure S1). EDS scans conducted on
seven different areas of the TEM grid revealed that the analyzed nanoparticles comprised both Fe and Gd (Figure 2B).
Taken together, these findings demonstrate that our synthesis
scheme results in stable Fe3O4@GdPB nanoparticles with
properties that are a composite of the constituent Fe3O4 and
GdPB nanoparticles.

Fe3O4@GdPB nanoparticles function as
effective MRI contrast agents
To determine if the Fe3O4@GdPB nanoparticles function
as effective MRI contrast agents, we conducted scans of
phantoms containing serial dilutions of Fe3O4@GdPB and
the constituent Fe3O4 and GdPB nanoparticles in a clinical
3 T MRI magnet. T1W scans demonstrated that the
Fe3O4@GdPB nanoparticles generated increased contrast
in a concentration-dependent manner (Figure 3A), ie,
increased brightening at increased concentrations, similar
to GdPB nanoparticles (previously characterized by us and
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Figure 1 Synthesis and characterization of Fe3O4@GdPB nanoparticles.
Notes: (A) The two-step scheme employed for synthesizing Fe3O4@GdPB nanoparticles. (B) Dynamic light scattering-based analysis of the size distributions (hydrodynamic
diameters) of Fe3O4, GdPB, and Fe3O4@GdPB nanoparticles. (C) Zeta potentials of Fe3O4, GdPB, and Fe3O4@GdPB nanoparticles. (D) Multiday mean sizes (hydrodynamic
diameters) of Fe3O4@GdPB nanoparticles measured by dynamic light scattering. (E) Visible-near infrared spectra of 1 mg/mL each of Fe3O4, GdPB, and Fe3O4@GdPB
nanoparticles.
Abbreviations: Fe3O4@GdPB, composite iron oxide-gadolinium-containing Prussian blue; Fe3O4, iron oxide; GdPB, gadolinium-containing Prussian blue; MRI, magnetic
resonance imaging; PBNP, Prussian blue nanoparticle; T1W, T1-weighted.
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Figure 2 Shape and composition of Fe3O4@GdPB NPs.
Notes: (A) Transmission electron microscopy image of Fe3O4@GdPB NPs. (B) Representative energy-dispersive X-ray spectrum of Fe3O4@GdPB NPs. The composition
was derived by built-in software from the attribution of the electronic energy profile for Fe, K, and Gd.
Abbreviation: Fe3O4@GdPB NPs, composite iron oxide-gadolinium-containing Prussian blue nanoparticles.
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Figure 3 MRI properties of Fe3O4@GdPB nanoparticles.
Notes: (A) T1W MR images of GdPB and Fe3O4@GdPB nanoparticles. (B) T2W
MR images of Fe3O4 and Fe3O4@GdPB nanoparticles. (C–D) T1-relaxation rate (1/
T1), as a function of Gd3+ concentration (mM) in (C) GdPB and (D) Fe3O4@GdPB
nanoparticles. (E–F) T2-relaxation rate (1/T2) as a function of Fe concentration
(mM) in (E) Fe3O4 and (F) Fe3O4@GdPB nanoparticles. (G) Relaxivities of Fe3O4,
GdPB, and Fe3O4@GdPB nanoparticles.
Abbreviations: Fe3O4@GdPB, composite iron oxide-gadolinium-containing
Prussian blue; Fe3O4, iron oxide; GdPB, gadolinium-containing Prussian blue; L-R,
left-to-right; MRI, magnetic resonance imaging; T1W, T1-weighted; T2W, T2weighted; nd, not determined for this study.

others).32,38,39 Similarly, T2W scans demonstrated that the
Fe3O4@GdPB nanoparticles generated increased contrast
in a concentration-dependent manner (Figure 3B), ie,
increased darkening with increasing concentrations, similar
to Fe3O4 nanoparticles, which have been well-described
in the literature.5,6 Based on image processing of multiple
T1W and T2W scans, we generated relaxation time plots as
a function of the contrast agent, namely Gd3+ ions for GdPB
(Figure 3C) and Fe3O4@GdPB (Figure 3D), and Fe for Fe3O4
(Figure 3E) and Fe3O4@GdPB (Figure 3F). These studies
yielded the r1 and r2 relaxivities (Figure 3G) of the Fe3O4@
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GdPB nanoparticles: r1 =5.5 mM−1 s-1 and r2 = 126 mM-1 s-1.
Although the r1 value of Fe3O4@GdPB is lower than that
of GdPB (38.4 mM-1 s-1), it is in a range similar to most
clinically approved, gadolinium-based T1 contrast agents at
a field strength of 3 T, including Magnevist (3.1 mM-1 s-1),
ProHance (2.8 mM-1 s-1), and Omniscan (3.2 mM-1 s-1).22
Additionally, a unique feature to our Fe3O4@GdPB is that
they can be guided to a particular anatomical location by an
external magnetic field, which cannot be achieved using GdPB
nanoparticles that have to rely on vasculature for anatomical
targeting. If improved contrast in T1W images is desired, the
synthesis of Fe3O4@GdPB can be appropriately modified to
incorporate a larger shell of GdPB with increased loading
of Gd3+ ions during synthesis over a smaller core of Fe3O4.
These results suggest that Fe3O4@GdPB can function as an
effective MRI contrast agent in T1W scans. In parallel with
these studies, we analyzed the T2 relaxivities of Fe3O4@GdPB
nanoparticles and obtained an r2 value of 126 mM-1 s-1 at a
3 T field strength. Although we do not explicitly utilize the
T2 contrast of our Fe3O4@GdPB nanoparticles in this study,
since the proposed use of our nanoparticles is for PTT of
tumors and we have previously discussed the limitations of
using T2W images especially for fluid-filled structures, our
results demonstrate that there may be future potential of these
agents as contrast agents in T2W imaging applications.

Fe3O4@GdPB nanoparticles function as
effective PTT agents
To quantify the photothermal heating properties of Fe3O4@
GdPB nanoparticles, we measured their heating as a function
of concentration, laser fluence, and multiple cycles of heating
and cooling. At a constant laser fluence of 1.875 W/cm2, the
nanoparticles were observed to heat to significantly higher
temperatures over the background (water; Figure 4A) with
changes in temperature approaching 20°C at a nanoparticle concentration of 0.01 mg/mL and ~35°C at nanoparticle
concentrations $0.05 mg/mL. At a constant nanoparticle
concentration of 1 mg/mL, Fe3O4@GdPB was observed to
heat to higher temperatures in a laser fluence-dependent manner (Figure 4B). Additionally, the nanoparticles retained their
photothermal heating properties over four cycles of heating
and cooling (Figure 4C) indicating their stability as photothermal agents over multiple heating cycles. Finally, studies
conducted to calculate the photothermal conversion efficiency
(Figure 4D) demonstrated that the nanoparticles had a photothermal conversion efficiency of 16.1%, which is consistent
with the previously determined photothermal conversion efficiency of Prussian blue nanoparticles (around 20%)35 despite
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Figure 4 Photothermal heating properties of Fe3O4@GdPB nanoparticles.
Notes: (A) Photothermal heating of varying concentrations of Fe3O4@GdPB nanoparticles at a constant laser fluence of 1.875 W/cm2 for 10 minutes. (B) Photothermal
heating of 1 mg/mL Fe3O4@GdPB nanoparticles as a function of varying 808 nm NIR laser fluence for 10 minutes. (C) Temperature profiles during cyclic heating of 1 mg/mL
Fe3O4@GdPB nanoparticles using an 808 nm NIR laser (laser on/off time: 10 minutes each). (D) Generation of heating and cooling curves of Fe3O4@GdPB nanoparticles to
calculate their photothermal conversion efficiency.
Abbreviations: Fe3O4@GdPB, composite iron oxide-gadolinium-containing Prussian blue; NIR, near infrared.



the fact that Fe3O4@GdPB nanoparticles are a composite of
both Fe3O4 and GdPB. These results demonstrate that Fe3O4@
GdPB nanoparticles are stable and effective PTT agents.

Fe3O4@GdPB nanoparticles are
cytotoxic to targeted cells upon
photothermal heating
To assess the intrinsic cytotoxicity of our Fe3O4@GdPB
nanoparticles as well as test whether they can function as effective PTT agents in the presence of cells, we added varying concentrations (0.01–0.5 mg/mL) of the nanoparticles to Neuro2a
cells (which will be used in our animal studies) in vitro, with and
without laser irradiation (Figure 5). Our studies demonstrated
that Fe3O4@GdPB nanoparticles exhibit marginal intrinsic
toxicity (in the absence of NIR laser irradiation) to Neuro2a
cells at concentrations $0.1 mg/mL. Neuro2a cell viability
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Figure 5 Intrinsic and PTT-induced cytotoxicity of varying concentrations of
Fe3O4@GdPB nanoparticles on Neuro2a cells in vitro.
Abbreviations: Fe3O4@GdPB, composite iron oxide-gadolinium-containing
Prussian blue; PTT, photothermal therapy.
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was slightly decreased to ~80% of the vehicle-treated controls
at these concentrations, suggesting that the nanoparticles can
be safely used for PTT of cells without intrinsic cytotoxicity
at concentrations lower than 0.1 mg/mL. Upon irradiation
with the NIR laser, the Fe3O4@GdPB nanoparticles generated significantly increased cytotoxicity to Neuro2a cells with
cell viability decreasing to ,60% of controls at nanoparticle
concentrations $0.1 mg/mL (under the experimental conditions). At a Fe3O4@GdPB concentration of 0.5 mg/mL, cell
viability was observed to decrease 3.5-fold to around 25%
upon irradiation compared to 80% viability in the absence of
the laser. Together, these results establish the concentrations
at which Fe3O4@GdPB nanoparticles do not exhibit intrinsic
cytotoxicity as well as demonstrate that the nanoparticles
retain their PTT properties in the presence of targeted cells.

Fe3O4@GdPB nanoparticles function as
effective contrast agents in T1W imaging of
tumors in a mouse model of neuroblastoma
As a step toward evaluating the efficacy of the Fe3O4@
GdPB nanoparticles as effective theranostic agents in vivo,
we tested the ability of the nanoparticles to function as
MRI contrast agents in an animal model of neuroblastoma.
Specifically, mice bearing palpable subcutaneous Neuro2a
tumors (average tumor size $5 mm) were divided into three
groups (n=5/group): 1) untreated: receiving no further treatment, 2) Fe3O4@GdPB-treated: tumor-bearing mice were
tail-vein injected with the nanoparticles, and 3) Fe3O4@
GdPB + magnet-treated: tumor-bearing mice were tail-vein
injected with the nanoparticles and an external magnetic
field was applied over the tumor for 10 minutes to direct
the circulating nanoparticles into the tumor. T1W scans
(Figure 6) of extracted tumor phantoms demonstrated that
tumors extracted from the Fe3O4@GdPB + magnet-treated
group exhibited increased contrast, ie, increased signal:noise
ratios relative to tumors extracted from the untreated group
and Fe3O4@GdPB-treated groups (Figure 6A). Tumors
(Figure 6B) from the Fe3O4@GdPB + magnet-treated group
exhibited an average signal:noise ratio of around 3.2, which
was significantly higher (P,0.05) than tumors from the
untreated group (~1.84) and Fe3O4@GdPB-treated (~2)
groups. Although further T1W imaging studies in a live
tumor-bearing animal are needed, these ex vivo studies
demonstrate that Fe3O4@GdPB nanoparticles can function as
effective contrast agents for T1W imaging of tumors in the
presence of external magnetic guidance. Our studies represent an important first step toward achieving this important
end goal of T1W resolution of tumors.
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Figure 6 T1W imaging characteristics of Fe3O4@GdPB nanoparticles in a Neuro2a
tumor model.
Notes: (A) Ex vivo signal:noise ratio measured in T1W images of tumors harvested
from untreated, Fe3O4@GdPB-treated, and Fe3O4@GdPB + magnet-treated
Neuro2a tumor-bearing mice showing significantly higher signal:noise ratio only in
the presence of both the Fe3O4@GdPB nanoparticles plus magnet (*P-value ,0.05).
(B) Raw T1W images of tumors harvested from untreated, Fe3O4@GdPB-treated,
and Fe3O4@GdPB + magnet-treated Neuro2a tumor-bearing mice.
Abbreviations: Fe3O4@GdPB, composite iron oxide-gadolinium-containing
Prussian blue; T1W, T1-weighted.

Fe3O4@GdPB nanoparticles function as
effective PTT agents in a mouse model
of neuroblastoma
Complementary to the T1W imaging studies, we conducted
studies assessing the PTT properties of the Fe3O4@GdPB nanoparticles in the Neuro2a mouse model of neuroblastoma. Neuro2a tumor-bearing mice (average tumor size $5 mm) were
divided into three groups (n=5/group): 1) untreated: receiving
no further treatment, 2) Fe3O4@GdPB-treated: where tumorbearing mice were tail-vein injected with the nanoparticles,
and 3) Fe3O4@GdPB + magnet-treated: where tumor-bearing
mice were tail-vein injected with the nanoparticles, and an
external magnetic field was applied over the tumor for 10 minutes to direct the circulating nanoparticles into the tumor.
Shortly after application of the external magnet, tumors of
mice in the Fe3O4@GdPB-treated group and Fe3O4@GdPB
+ magnet-treated group were irradiated with the NIR laser
(Figure 7). Tumor surface temperatures as measured by
infrared thermometry demonstrated that mice in the Fe3O4@
GdPB + magnet-treated group achieved an average tumor
surface temperature of 52°C after 10 minutes of irradiation,
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Figure 7 Photothermal therapy characteristics of Fe3O4@GdPB nanoparticles in a Neuro2a tumor model.
Notes: (A) Tumor temperatures as a function of time measured by an infrared thermal camera in Neuro2a tumor-bearing mice that are treated with either Fe3O4@GdPB
nanoparticles or Fe3O4@GdPB nanoparticles + magnet. (B) Kaplan–Meier survival curves of Neuro2a tumor-bearing mice that are untreated, Fe3O4@GdPB nanoparticles +
NIR laser-treated, or Fe3O4@GdPB nanoparticles + magnet + NIR laser-treated. (C–E) Tumor growth in Neuro2a-tumor bearing mice that are (C) untreated, (D) Fe3O4@
GdPB nanoparticles + NIR laser-treated, and (E) Fe3O4@GdPB nanoparticles + magnet + NIR laser-treated. Each line represents a single tumor-bearing animal.
Abbreviations: Fe3O4@GdPB, composite iron oxide-gadolinium-containing Prussian blue; NIR, near infrared.

which was marginally higher than the tumor surface temperature of 50°C achieved in the Fe3O4@GdPB-treated group
(Figure 7A). Furthermore, both groups achieved tumor surface temperatures that were on average .20°C above the initial tumor surface temperatures (~25°C). Our observations of
significantly elevated temperatures over basal temperatures
even in the Fe3O4@GdPB-treated group are not unexpected
given that our previous studies in the same Neuro2a model
have demonstrated that NIR irradiation of tumors even in the
absence of PTT agents can elevate tumor surface temperatures by 5°C–10°C.35 Additionally, when using nanoparticlebased PTT agents particularly at short time intervals after
tail-vein injection (ie, ,1 h), further heating is caused by
nanoparticles circulating through tumor vasculature that are
irradiated by the laser (intravascular heating). The addition of
magnet concentrates a larger amount of nanoparticles within
the tumors, which accounts for the heating observed in the
Fe3O4@GdPB + magnet-treated group above the Fe3O4@
GdPB-treated. Strategies that can be employed to increase
the temperature elevation achieved in the Fe3O4@GdPB +
magnet-treated group over the Fe3O4@GdPB-treated group
are to apply the external magnet for longer periods of time, or

International Journal of Nanomedicine 2017:12

wait until the majority of the nanoparticles are cleared from
circulation (typically 1–2 hours, unless the nanoparticles are
specifically designed for longer circulation times).
Kaplan–Meier survival plots demonstrated that mice
in both the Fe 3O 4@GdPB-treated group and Fe 3O 4@
GdPB + magnet-treated group exhibited significantly higher
survival than the mice in the untreated group as determined by a log-rank test (P,0.05; Figure 7B). Mice in the
Fe3O4@GdPB + magnet-treated group exhibited marginally
increased survival as compared to mice in the Fe3O4@GdPBtreated group although this was not statistically significant.
Further optimization studies with increased power, ie,
increased number of mice per group, are required to completely characterize the observed PTT effects and their
implications for animal survival. Finally, tumor growth
curves demonstrate that PTT applied in both the Fe3O4@
GdPB-treated and Fe3O4@GdPB + magnet-treated groups
causes slower tumor progression as evidenced by the lower
tumor growth curve slopes relative to mice in the untreated
group. Once again, tumor growth in the Fe3O4@GdPB +
magnet-treated group appeared to be marginally slower than
in mice in the Fe3O4@GdPB-treated group but this was not
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observed to be statistically significant. Taken together, our
findings suggest that Fe3O4@GdPB nanoparticles function as
effective PTT agents resulting in slower tumor growth rates
and increased survival relative to untreated mice although
further studies are needed to identify the optimal modes for
applying the external magnet and NIR laser.

Conclusion
We have presented Fe3O4@GdPB nanoparticles as effective
theranostic agents, particularly for T1W imaging and PTT
of tumors. Our facile synthesis scheme resulted in stable
Fe 3O 4@GdPB nanoparticles that exhibited composite
properties of both the Fe3O4 and GdPB (Figures 1 and 2). The
nanoparticles possessed the ability to function as effective
contrast agents in both T1W and T2W scans (Figure 3) as
well as effective PTT agents (Figure 4). The Fe3O4@GdPB
nanoparticles generated cytotoxicity of targeted Neuro2a
cells upon laser irradiation in vitro (Figure 5). Ex vivo imaging studies demonstrated that the nanoparticles increased
signal:noise ratios in T1W scans of tumor phantoms relative
to controls (Figure 6). Finally, the nanoparticles functioned
as effective PTT agents in vivo by decreasing tumor growth
rate and increasing survival relative to untreated controls
(Figure 7). Our findings demonstrate the theranostic utility of our Fe3O4@GdPB nanoparticles and represent an
important prelude to their eventual preclinical to clinical
translation in treating cancer.
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Figure S1 Representative TEM images of (A) Fe3O4 and (B) Fe3O4@GdPB nanoparticles as synthesized.
Note: The nanoparticles size analysis was performed using ImageJ by manually measuring the size of the individual nanoparticles from the TEM images, which yielded a mean
particle diameter of 8.0±2.2 nm for Fe3O4 and 28.2±8.3 nm for Fe3O4@GdPB.
Abbreviations: Fe3O4@GdPB, composite iron oxide-gadolinium-containing Prussian blue; TEM, transmission electron microscopy.
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